[Analysis of drug resistance spectrum and its mechanism in 1017 clinical bacterial isolates].
OBJECTIVE
To investigate the drug susceptibility of the clinical bacterial isolates to provide evidence for more adequate use of antibiotics.


METHODS
Altogether 1017 clinical bacterial isolates were identified by BD Phoenix and tested for resistance against antimicrobial agents by K-B method. WHONET5 was applied for the analysis.


RESULTS
The most frequent bacteria detected included P. aeruginosa (19.37%), coagulase-negative Staphylococci (CNS, 17.70%), E. coli (13.27%), S. aureu (SA, 12.09%), E. faecalis (11.8%), and K. pneumoniae (7.57%). In gram-negative isolates, the susceptibility rate of imipenem was 81.5%, and that of ceftazidime was above 70%. The incidences of E.coli and K. pneumoniae isolates producing extended spectrum beta-lactamase (ESBLs) were 34.8% and 45.5% respectively. In gram-positive isolates, the susceptibility rates of vancomycin and Teicoplanin were 98.8% and 100.0% respectively, and those of furazolidone, imipenem, amikacin, piperacillin/ tazobactam were above 70%. The oxacillin resistant rates of CNS and SA were 78.2% and 46.8%.


CONCLUSIONS
The 1017 clinical bacterial isolates are characterized by high ratio of ESBL production and oxacillin resistance, suggesting the importance of adequate use of antimicrobial agents and effective control measures for reducing the drug resistance and preventing the spread of multi drug- resistant bacteria.
Geng
Sui-na
SN
Clinical Laboratory, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Rui
Yong-yu
YY
Wang
Qian
Q
Mou
Cheng-hui
CH
Zhou
Xiao-hong
XH
Zhang
Jie
J
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002442:Ceftazidime / Q000494:pharmacology; D024881:Drug Resistance, Bacterial; D004926:Escherichia coli / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D010068:Oxacillin / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000302:isolation & purification; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000302:isolation & purification; D001618:beta-Lactamases / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D015378:Imipenem; D002442:Ceftazidime; D001618:beta-Lactamases; D010068:Oxacillin